FDA批准PaxVax公司口服单剂量霍乱疫苗研发申请

2012-04-25 cyy123 cyy123

近日,PaxVax公司口服单剂量霍乱疫苗研发新药申请(IND)获得美国食品药监局(FDA)批准。PXVX-0200是一种对抗霍乱的活性疫苗,先前曾以商品名为Orochol在其他六个国家获得批准。 公司计划于今年晚些时候开始这种疫苗III期研究。PaxVax和荷兰的SynCo 公司合作,用于生产用于霍乱疫苗临床试验材料的生产。 Paxvax公司首席执行官Kenneth Kelley说:“我们希望

近日,PaxVax公司口服单剂量霍乱疫苗研发新药申请(IND)获得美国食品药监局(FDA)批准。PXVX-0200是一种对抗霍乱的活性疫苗,先前曾以商品名为Orochol在其他六个国家获得批准。

公司计划于今年晚些时候开始这种疫苗III期研究。PaxVax和荷兰的SynCo 公司合作,用于生产用于霍乱疫苗临床试验材料的生产。

Paxvax公司首席执行官Kenneth Kelley说:“我们希望PXVX-0200成为在第一个美国上市的霍乱疫苗,同时成为全球第一种口服的霍乱疫苗。而且霍乱被FDA认定为被忽视的热带疾病,我们的PXVX-0200用手有限审定权”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1634297, encodeId=5e95163429e58, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Fri Aug 24 16:18:00 CST 2012, time=2012-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086174, encodeId=45a920861e445, content=<a href='/topic/show?id=99d698902ce' target=_blank style='color:#2F92EE;'>#霍乱疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98902, encryptionId=99d698902ce, topicName=霍乱疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Nov 04 12:18:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839151, encodeId=eaf41839151ea, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed May 30 07:18:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299724, encodeId=da071299e2429, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348428, encodeId=018e1348428b1, content=<a href='/topic/show?id=964f98898f9' target=_blank style='color:#2F92EE;'>#霍乱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98898, encryptionId=964f98898f9, topicName=霍乱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1634297, encodeId=5e95163429e58, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Fri Aug 24 16:18:00 CST 2012, time=2012-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086174, encodeId=45a920861e445, content=<a href='/topic/show?id=99d698902ce' target=_blank style='color:#2F92EE;'>#霍乱疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98902, encryptionId=99d698902ce, topicName=霍乱疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Nov 04 12:18:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839151, encodeId=eaf41839151ea, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed May 30 07:18:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299724, encodeId=da071299e2429, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348428, encodeId=018e1348428b1, content=<a href='/topic/show?id=964f98898f9' target=_blank style='color:#2F92EE;'>#霍乱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98898, encryptionId=964f98898f9, topicName=霍乱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1634297, encodeId=5e95163429e58, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Fri Aug 24 16:18:00 CST 2012, time=2012-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086174, encodeId=45a920861e445, content=<a href='/topic/show?id=99d698902ce' target=_blank style='color:#2F92EE;'>#霍乱疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98902, encryptionId=99d698902ce, topicName=霍乱疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Nov 04 12:18:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839151, encodeId=eaf41839151ea, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed May 30 07:18:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299724, encodeId=da071299e2429, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348428, encodeId=018e1348428b1, content=<a href='/topic/show?id=964f98898f9' target=_blank style='color:#2F92EE;'>#霍乱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98898, encryptionId=964f98898f9, topicName=霍乱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-05-30 bugit
  4. [GetPortalCommentsPageByObjectIdResponse(id=1634297, encodeId=5e95163429e58, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Fri Aug 24 16:18:00 CST 2012, time=2012-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086174, encodeId=45a920861e445, content=<a href='/topic/show?id=99d698902ce' target=_blank style='color:#2F92EE;'>#霍乱疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98902, encryptionId=99d698902ce, topicName=霍乱疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Nov 04 12:18:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839151, encodeId=eaf41839151ea, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed May 30 07:18:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299724, encodeId=da071299e2429, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348428, encodeId=018e1348428b1, content=<a href='/topic/show?id=964f98898f9' target=_blank style='color:#2F92EE;'>#霍乱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98898, encryptionId=964f98898f9, topicName=霍乱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 lqvr
  5. [GetPortalCommentsPageByObjectIdResponse(id=1634297, encodeId=5e95163429e58, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Fri Aug 24 16:18:00 CST 2012, time=2012-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086174, encodeId=45a920861e445, content=<a href='/topic/show?id=99d698902ce' target=_blank style='color:#2F92EE;'>#霍乱疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98902, encryptionId=99d698902ce, topicName=霍乱疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Nov 04 12:18:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839151, encodeId=eaf41839151ea, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed May 30 07:18:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299724, encodeId=da071299e2429, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348428, encodeId=018e1348428b1, content=<a href='/topic/show?id=964f98898f9' target=_blank style='color:#2F92EE;'>#霍乱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98898, encryptionId=964f98898f9, topicName=霍乱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 klivis

相关资讯

拜耳向欧盟提交拜瑞妥(Xarelto)上市许可申请

2012年4月12日,拜耳(Bayer)旗下拜耳医药保健公司(Bayer HealthCare)称,已向欧洲药品管理局提交口服抗凝血剂拜瑞妥Xarelto(又名rivaroxaban,利伐沙班)的上市许可申请(marketing authorization),用于治疗肺栓塞(pulmonary embolism,PE)及预防成人中深层静脉血栓及PE的复发。 所提交的申请是基于一项关键性、全球性的

Biovest计划在加拿大提交个性化癌症疫苗BiovaxID上市审批申请

Biovest公司计划首先在加拿大提交个性化癌症疫苗BiovaxID的上市审批申请,这将是首个上市的淋巴瘤疫苗。 2012年4月12日,Biovest公司已选择加拿大,作为提交其个性化癌症疫苗BiovaxID上市审批申请的首个国家。该疫苗用于治疗滤泡性非霍奇金淋巴瘤(follicular non-Hodgkin lymphoma),靶向作用于引起该疾病的恶性B细胞。BiovaxID可能会是面向淋

FDA批准Mylan公司Ibandronate钠片仿制药申请

Mylan医药公司Ibandronate钠片(150毫克)仿制药申请获得美国食品药监局(FDA)批准。 Ibandronate钠片是仿制的罗氏公司的Boniva,用于治疗绝经期妇女的骨质疏松。 Boniva去年在美国的销售额接近5.2亿美元,而且Mylan现在有173个仿制药正等待FDA的批准,这些药的总共年销售额高达1000亿美元。 Mylan公司是一家专门生产仿制药的公司,产品在全球15

糖尿病性黄斑水肿治疗新药Optina中期试验审查结束

据悉,生物制药公司——Ampio制药公司(纳斯达克:AMPE)于近日宣布,它已经完成了对计划中的OptinaTM治疗糖尿病性黄斑水肿试验纳入的前50%患者的中期审查。 该实验在加拿大多伦多St. Michael医院进行,考察OptinaTM每日两次口服剂量的安全性和有效性,通过OCT(光学相干断层扫描)确定黄斑水肿的减轻程度。OCT是一种测量黄斑区厚度的方法,黄斑区是视网膜负责颜色和视敏度的区域

默沙东及Ariad公司ridaforolimus获批希望愈加渺茫

默沙东($MRK)公司和Ariad制药公司靶向性抗癌药物ridaforolimus获批的希望愈加渺茫,因FDA专家小组投票,不推荐该药用于肉瘤(sarcomas)的治疗。FDA具有最终的决定权,并将于最后期限即6月5号决定该药物的命运。 有关该药的审批,专家小组成员中,13位投了反对票,仅1位投了赞成票。许多分析家已预计到FDA专家小组会拒绝默沙东($MRK)公司和Ariad公司的申请,尤其在F

Pozen公司阿司匹林组合药物PA32540 两项III期研究结果喜人

2012年3月22日,Pozen($POZN)公司宣布,在心脏病患者中开展的有关阿司匹林组合药物PA32540的2个III期研究得到了积极的数据,为今年晚些时期的新药申请铺平了道路。Pozen($POZN)公司的股价在今晨也出现了大的反弹,在早盘交易中,其股票上涨19%。 总部位于北卡罗来纳州教堂山的Pozen公司在PA32540的2项III期研究中招募了1000多位患者。PA32540是速释o